Emavusertib in Combination with Gemcitabine and Nab-paclitaxel in Metastatic or Unresectable Pancreatic Ductal Adenocarcinoma AACR 2025 Poster

• About Company Overview Management Board of Directors Advisory Boards

• Collaborations Partner Collaborations Scientific & Research Collaborations

• Patients Patients Overview Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL Understanding Primary CNS Lymphoma Compassionate Use Policy

• Pipeline Pipeline Overview Emavusertib (CA-4948) Fimepinostat CA-170 CA-327

• Scientific Resources

• Investors Overview Press Releases Events and Presentations Corporate Governance Committee Composition Contact the Board Financial Information SEC Filings Annual Reports IRS Form 8937 Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage Contact Us

• Careers Life at Curis Open Positions Benefits

• Contact

• Company Overview

• Management

• Board of Directors

• Advisory Boards

• Partner Collaborations

• Scientific & Research Collaborations

• Patients Overview

• Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL

• Understanding Primary CNS Lymphoma

• Compassionate Use Policy

• Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL

• TakeAim Lymphoma

• TakeAim Leukemia

• TakeAim CLL

• Pipeline Overview

• Emavusertib (CA-4948)

• Fimepinostat

• CA-170

• CA-327

• Overview

• Press Releases

• Events and Presentations

• Corporate Governance Committee Composition Contact the Board

• Financial Information SEC Filings Annual Reports IRS Form 8937

• Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage

• Contact Us

• Committee Composition

• Contact the Board

• SEC Filings

• Annual Reports

• IRS Form 8937

• Interactive Chart

• Historical Stock Lookup

• Analyst Coverage

• Life at Curis

• Open Positions

• Benefits